Clinical

Dataset Information

0

Phase 1 Trial of Lonsurf with Irinotecan and Bevacizumab


ABSTRACT: Interventions: 1 cycle is 28days. Lonsurf(25mg/m2)is administered orally twice daily in 1-5days and 8-12 days. Irinotecan(100mg/m2) and Bevacizumab(5mg/kg) is administered by injection in day 1 and day15. Primary outcome(s): Recommended dose:RD Study Design: single arm study, open(masking not used), uncontrolled control, single assignment, treatment purpose

DISEASE(S): Advanced Colorectal Cancer

PROVIDER: 2615622 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

Similar Datasets

| 2634299 | ecrin-mdr-crc
| 2641267 | ecrin-mdr-crc
| 2646936 | ecrin-mdr-crc
| 2628236 | ecrin-mdr-crc
| 2631090 | ecrin-mdr-crc
| 2632430 | ecrin-mdr-crc
| 2611187 | ecrin-mdr-crc
| 97953 | ecrin-mdr-crc
2020-05-26 | GSE145898 | GEO
| 2609743 | ecrin-mdr-crc